Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1).

Lennox BR, Tomei G, Vincent SA, Yeeles K, Pollard R, Palmer-Cooper E, Jones P, Zandi MS, Coles A.

J Neurol Neurosurg Psychiatry. 2018 Jun 11. pii: jnnp-2018-318124. doi: 10.1136/jnnp-2018-318124. [Epub ahead of print] No abstract available.

PMID:
29891740
2.

NMDAR antibodies in first episode psychosis: conclusions too inflammatory given results? - Authors' reply.

Lee MM, Oke J, Palmer-Cooper EC, Lennox BR.

Lancet Psychiatry. 2017 May;4(5):356-357. doi: 10.1016/S2215-0366(17)30139-6. No abstract available.

PMID:
28456292
3.

Serum neuronal cell-surface antibodies in first-episode psychosis-Authors' reply.

Lennox BR, Pollak T, Palmer-Cooper EC, Scoriels L, Harrison PJ, Jones PB, Lang B, Crowley H, Marks J, Vincent A.

Lancet Psychiatry. 2017 Mar;4(3):187-188. doi: 10.1016/S2215-0366(17)30053-6. No abstract available.

PMID:
28236947
4.

Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study.

Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, Lang B, Fox H, Ferry B, Scoriels L, Crowley H, Jones PB, Harrison PJ, Vincent A; PPiP study team.

Lancet Psychiatry. 2017 Jan;4(1):42-48. doi: 10.1016/S2215-0366(16)30375-3. Epub 2016 Dec 8.

Supplemental Content

Loading ...
Support Center